Antony Mattessich | BiotechTV

top of page

1 day ago

Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL

CEO Antony Mattessich describes the company's approach and the advantages he believes it has over other TPD. Plus, the lead program...

OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO

Jun 12, 2023

Company News

OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO

Ocular Therapeutix CEO Antony Mattessich describes the 12-month data his company has reported for its extended release TKI for wet AMD.

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Savills' Life Sciences Overview

bottom of page

Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL

OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO

Follow BiotechTV

Sponsors

Sponsor Spotlight